Novartis AG (NVSN) — Free Cash Flow Generation Index

Latest as of March 2026: 0.78x

Novartis AG (NVSN) has a Free Cash Flow Generation Index of 0.78x as of March 2026. Free cash flow of MX$2.87 Billion represents 1% of operating cash flow (MX$3.68 Billion). Read Novartis AG (NVSN) total liabilities for a breakdown of total debt and financial obligations.

FCF Generation Index

0.78x
Free Cash Flow / Operating CF

Free Cash Flow

MX$2.87 Billion
MXN

Operating Cash Flow

MX$3.68 Billion
MXN

Capital Expenditures

MX$807.00 Million
MXN

Novartis AG Free Cash Flow Generation Index (2014–2025)

Historical FCF Generation Index trend for Novartis AG across 12 annual periods. Explore reinvestment intensity of Novartis AG to see what proportion of operating cash flow is directed to capital expenditures.

Annual Free Cash Flow Generation for Novartis AG (2014–2025)

Year-by-year Free Cash Flow Generation Index for Novartis AG. For the full company profile including market capitalisation, see Novartis AG market capitalisation.

Year FCG Index Free Cash Flow (MXN) Operating CF Capital Expenditures YoY Change
2025 0.80x MX$15.24 Billion MX$19.14 Billion MX$3.90 Billion ▲ +1.6%
2024 0.78x MX$13.80 Billion MX$17.62 Billion MX$3.81 Billion ▼ -4.3%
2023 0.82x MX$13.12 Billion MX$16.02 Billion MX$2.90 Billion ▲ +0.8%
2022 0.81x MX$11.56 Billion MX$14.24 Billion MX$1.20 Billion ▲ +1.2%
2021 0.80x MX$12.10 Billion MX$15.07 Billion MX$1.38 Billion ▼ -1.0%
2020 0.81x MX$11.06 Billion MX$13.65 Billion MX$1.27 Billion ▼ -2.8%
2019 0.83x MX$11.37 Billion MX$13.62 Billion MX$1.38 Billion ▲ +9.1%
2018 0.76x MX$10.92 Billion MX$14.27 Billion MX$1.25 Billion ▼ -2.2%
2017 0.78x MX$9.88 Billion MX$12.62 Billion MX$1.32 Billion ▼ -37.5%
2016 1.25x MX$14.35 Billion MX$11.47 Billion MX$2.88 Billion ▲ +4.3%
2015 1.20x MX$14.26 Billion MX$11.90 Billion MX$2.37 Billion ▲ +0.9%
2014 1.19x MX$16.52 Billion MX$13.90 Billion MX$2.62 Billion
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).